Casi Pharmaceuticals: China NMPA accepts NDA from Juventas for CNCT19

CASI Pharmaceuticals announces that China National Medical Products Administration has accepted the new drug application from Juventas Cell Therapy for CNCT19, an investigational CD-19 directed CAR-T therapy, for the treatment of adult patients with relapsed/refractory B-Cell Acute Lymphoblastic Leukemia.